Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ACGN

Aceragen (ACGN) Stock Price, News & Analysis

Aceragen logo

About Aceragen Stock (NASDAQ:ACGN)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$0.38
$0.38
50-Day Range
$0.38
$0.90
52-Week Range
$0.36
$16.00
Volume
N/A
Average Volume
N/A
Market Capitalization
$3.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. Its clinical development pipeline includes ACG-701, which is in Phase 2 clinical trial for cystic fibrosis pulmonary exacerbations, as well as for melioidosis; and ACG-801 for farber disease. Aceragen, Inc. has a collaboration and option agreement with Scriptr Global, Inc. to identify, research, and develop gene therapy candidates for the treatment, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia. The company was formerly known as Idera Pharmaceuticals, Inc. and changed its name to Aceragen, Inc. in January 2023. Aceragen, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.

Remove Ads
Receive ACGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aceragen and its competitors with MarketBeat's FREE daily newsletter.

ACGN Stock News Headlines

ACGN - Aceragen, Inc.
Your Wealth is Under Attack
Please don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your free gift, and see how Trump's victory could spark major gains for gold.
Aceragen, Inc. to Delist from The Nasdaq Stock Market
Aceragen: Q1 Earnings Snapshot
See More Headlines

ACGN Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Aceragen investors own include Agenus (AGEN), Altamira Therapeutics (CYTO), Alimera Sciences (ALIM), Alpine Summit Energy Partners (ALPS), Angion Biomedica (ANGN), AirNet Technology (ANTE) and Aptorum Group (APM).

Company Calendar

Today
3/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ACGN
Employees
26
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$4.86 million
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
6,196,000
Market Cap
$3.20 million
Optionable
Not Optionable
Beta
N/A
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:ACGN) was last updated on 3/29/2025 by MarketBeat.com Staff
From Our Partners